Prostate Cell News Volume 8.48 | Dec 15 2017

TOP STORY

SPOP Mutation Drives Prostate Neoplasia without Stabilizing Oncogenic Transcription Factor ERG

Expression of prostate cancer–associated SPOP mutations in genetically engineered mouse models of SPOP-mutant prostate cancer did not result in the expression of ERG protein in histologically normal prostate glands, high-grade prostatic intraepithelial neoplasia, invasive adenocarcinoma, or prostate organoids. [J Clin Invest] Full Article

(Ranked by impact factor of the journal)

PSMA-Targeted Polyinosine/Polycytosine Vector Induces Prostate Tumor Regression and Invokes an Antitumor Immune Response in Mice

Researchers designed a nonviral vector, PEI-PEG-DUPA, comprising polyethylenimine–polyethyleneglycol (PEI–PEG) tethered to the prostate surface membrane antigen (PSMA) ligand, 2-[3-(1, 3-dicarboxy propyl)ureido] pentanedioic acid (DUPA), to treat prostate cancer. [Proc Natl Acad Sci USA] Abstract

Single-Cell RNA-Seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell Cycle-Related Transcription and Attenuated Androgen Response

Increasing evidence suggests the presence of minor cell subpopulations in prostate cancer that are androgen independent and poised for selection as dominant clones after androgen-deprivation therapy. The authors investigated this phenomenon by stratifying cell subpopulations based on transcriptome profiling of 144 single LNCaP prostate cancer cells treated or untreated with androgen after cell cycle synchronization. [Cancer Res] Abstract

Silencing of miR-193a-5p Increases the Chemosensitivity of Prostate Cancer Cells to Docetaxel

miR-193a-5p was upregulated in prostate cancer (PC) tissues and PC cell lines, with significant suppression of PC3 cell apoptosis induced by oxidative stress. [J Exp Clin Cancer Res] Full Article

Adaptive Phenotype Drives Resistance to Androgen Deprivation Therapy in Prostate Cancer

Western blotting, immunocytochemistry, invasion and reporter assays, and in vivo studies were performed to characterize androgen resistant sublines phenotype in comparison to the parental cell line LNCaP. [Cell Commun Signal] Full Article

Oncogenic Non-Coding RNA NEAT1 Promotes the Prostate Cancer Cell Growth through the SRC3/IGF1R/AKT Pathway

Investigators found a novel SRC3 binding ncRNA that can promote the prostate cancer cell growth through SRC3/IGF1R/AKT pathway. [Int J Biochem Cell Biol] Abstract

GANT-61 and GDC-0449 Induce Apoptosis of Prostate Cancer Stem Cells through a GLI-Dependent Mechanism

Inhibition of the Sonic hedgehog signaling pathway by GANT-61 induced apoptosis with more efficacy than by GDC-0449 in prostate cancer (PC) stem cells and PC cell lines. [J Cell Biochem] Abstract

MiRNALet-7a Mediates Prostate Cancer PC-3 Cell Invasion, Migration by Inducing Epithelial-Mesenchymal Transition through CCR7/MAPK Pathway

The authors investigated whether C-C chemokine receptor type 7 (CCR7) overexpression was associated with a decrease in the expression of miRNA let-7a in invasion and metastasis of prostate cancer cell. [J Cell Biochem] Abstract

Curcumin Derivative Epigenetically Reactivates Nrf2 Antioxidative Stress Signaling in Mouse Prostate Cancer TRAMP C1 Cells

Researchers investigated the effects of (3E,5E)-3,5-Bis(3,4,5-trimethoxybenzylidene) -tetrahydrothiopyran-4-one and (3E,5E)-3,5-Bis(3,4,5-trimethoxybenzylidene) -tetrahydropyran-4-one, two synthetic curcumin derivatives, on restoring Nrf2 activity in TRAMP C1 cells. [Chem Res Toxicol] Abstract

Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities

The authors discuss the main metabolic features of prostate cancer with a particular focus on the link between oncogene-directed cancer metabolic regulation, metabolism rewiring, and epigenetic regulation. [Cold Spring Harb Perspect Med] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Constellation Pharmaceuticals Announces First Patient Dosed in Phase Ib/II PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate Cancer

Constellation Pharmaceuticals, Inc. announced that the first patient has been dosed in its Phase Ib/II PROSTAR study of CPI-1205, a small-molecule inhibitor of EZH2, combined with enzalutamide or abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer. [Constellation Pharmaceuticals, Inc.] Press Release

Sophiris Bio Announces Complete Enrollment in Phase IIb Topsalysin Study of Localized Prostate Cancer

Sophiris Bio Inc. announced that it has completed enrollment in its Phase IIb study to evaluate the safety and tolerability of topsalysin in treating men with clinically significant localized prostate cancer. [Sophiris Bio Inc.] Press Release

French Researchers Hope New Chief Will Revitalize Troubled Funding Agency

French scientists are hopeful that the newly appointed chief of a major research-funding agency will revive an organization suffering from squeezed budgets and staff discontent. [Nature News] Editorial

Iran’s Supreme Court Confirms Death Sentence for Jailed Scholar

Iran’s Supreme Court has upheld the death sentence handed to Ahmadreza Djalali, a scholar who worked in Europe, according to the human-rights group Amnesty International. [Nature News] Editorial

NEW The London Stem Cell Network Symposium 2018
February 26, 2018
London, United Kingdom

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Scientist – Prostate Oncobiology (CRUK Manchester Institute)

Assistant/Associate Professor – Prostate Cancer (Northwestern University)

Postdoctoral Fellowship – Prostate Cancer (Duke University Medical Center)

PhD Studentship – Prostate Cancer (CRUK Manchester Institute)

Postdoctoral Positions – Cancer Biology (University of Pennsylvania)

Assistant Professor – Prostate Cancer (University of Illinois)

PhD Student Position – Prostate Cancer (Bellvitge Biomedical Research Institute)

Postdoctoral Position – Prostate Cancer (University of Minnesota)

Faculty Position – Cancer Research (Duke University)

Postdoctoral Position – Drug Discovery for Advanced Prostate Cancer (Lerner Research Institute)

Postdoctoral Position – Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Prostate Related Diseases (Baylor College of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.